Original Article

Long-Term Treatment of Primary Pulmonary Hypertension with Aerosolized Iloprost, a Prostacyclin Analogue

Marius M. Hoeper, M.D., Michael Schwarze, Stefan Ehlerding, Angelika Adler-Schuermeyer, R.N., Edda Spiekerkoetter, M.D., Jost Niedermeyer, M.D., Michael Hamm, M.D., and Helmut Fabel, M.D.

N Engl J Med 2000; 342:1866-1870June 22, 2000

Abstract

Background

Continuous intravenous infusion of epoprostenol (prostacyclin) is an effective treatment for primary pulmonary hypertension. This approach requires the insertion of a permanent central venous catheter, with the associated risk of serious complications. Recently, aerosolized iloprost, a stable prostacyclin analogue, has been introduced as an alternative therapy for severe pulmonary hypertension.

Full Text of Background...

Methods

We evaluated the effects of aerosolized iloprost on exercise capacity and hemodynamic variables over a one-year period in patients with primary pulmonary hypertension.

Full Text of Methods...

Results

Twenty-four patients with primary pulmonary hypertension received aerosolized iloprost at a daily dose of 100 or 150 μg for at least one year. The mean (±SD) distance covered in the six-minute walk test increased from 278±96 m at base line to 363± 135 m after 12 months (P<0.001). During the same period, the mean pulmonary arterial pressure before the inhalation of iloprost declined from 59±10 mm Hg to 52±15 mm Hg (P=0.006), cardiac output increased from 3.8±1.4 liters per minute to 4.4±1.3 liters per minute (P=0.02), and pulmonary vascular resistance declined from 1205±467 dynseccm^–5 to 925±469 dynseccm^–5 (P<0.001). The treatment was generally well tolerated, except for mild coughing, minor headache, and jaw pain in some patients.

Full Text of Results...

Conclusions

Long-term treatment with aerosolized iloprost is safe and has sustained effects on exercise capacity and pulmonary hemodynamics in patients with primary pulmonary hypertension.

Full Text of Discussion...

Read the Full Article...

Media in This Article

Figure 2Regression Analysis of Short-Term Changes in Pulmonary Vascular Resistance in Response to Inhaled Iloprost at Base Line and Changes in Preinhalation Pulmonary Vascular Resistance after 12 Months of Treatment with Aerosolized Iloprost.

Figure 1Pulmonary Vascular Resistance at Base Line and after 3 Months and 12 Months of Treatment with Aerosolized Iloprost.

Article Activity

153 articles have cited this article

Article

Several studies have shown that continuous intravenous epoprostenol (prostacyclin) improves exercise tolerance, hemodynamic variables, and survival in patients with primary pulmonary hypertension.1-7 This treatment, however, has two substantial drawbacks. One is the occurrence of tolerance, which in some patients necessitates continuous dose escalation and therefore contributes to the high cost of treatment. The other, clinically more pertinent problem is the risk of serious infection, catheter thrombosis, and pump failure associated with the permanent central venous catheter and delivery system. Although the risk of these complications has been reported to be low,4,7 they are potentially life-threatening.

These shortcomings might be overcome by the administration of aerosolized iloprost,8 a stable prostacyclin analogue, as suggested by Olschewski et al.9,10 When administered by inhalation, iloprost is a potent pulmonary vasodilator with more pronounced short-term hemodynamic effects than inhaled nitric oxide in patients with primary pulmonary hypertension.11 Preliminary studies have shown that intermittent inhalation of iloprost has beneficial short-term effects in patients with primary and secondary pulmonary hypertension.11,12 However, only limited data are available on the long-term efficacy of treatment with aerosolized iloprost in patients with primary pulmonary hypertension.9

We studied the effects of administering aerosolized iloprost over a one-year period to patients with primary pulmonary hypertension.

Methods

Patients

We studied the clinical course of consecutive patients who were referred to our center for the treatment of pulmonary hypertension between March 1997 and June 1998 and who had primary pulmonary hypertension according to the diagnostic criteria of the National Institutes of Health Registry on Primary Pulmonary Hypertension.13 Patients with secondary pulmonary hypertension were excluded, as were patients with severe right heart failure who were receiving catecholamines at the time of their initial presentation and those lost to follow-up.

Treatment and Follow-up

In Germany, neither intravenous epoprostenol nor aerosolized iloprost has been licensed for the treatment of pulmonary hypertension. At our center, aerosolized iloprost is being offered, on a compassionate-use basis, as first-line therapy for the majority of patients with advanced primary pulmonary hypertension. This approach was approved by our institution's ethics committee; all patients in this study were informed about the investigational character of the treatment and gave written informed consent.

To be eligible for treatment with aerosolized iloprost, patients had to have pulmonary hypertension with severe limitation of exercise capacity (New York Heart Association functional class III or IV) that was refractory to conventional medical treatment, including the use of calcium-channel blockers. Exercise capacity was determined by the six-minute walk test after the patient had performed one or two walks to become familiar with the route.14

Hemodynamic variables were assessed by catheterization of the right side of the heart. Cardiac output was measured by the thermodilution technique.15 After the base-line hemodynamic variables had been recorded, the short-term hemodynamic response to aerosolized iloprost was measured. For that purpose, 50 μg of iloprost (Ilomedin, Schering, Berlin, Germany) was diluted in 5 ml of isotonic saline, aerosolized in a jet nebulizer (Ilo-Neb, Nebu-Tec, Elsenfeld, Germany) and administered over a period of 10 to 15 minutes, which resulted in a cumulative dose of nebulized iloprost between 14 and 17 μg. Immediately after inhalation and every 15 minutes thereafter for up to 1 hour, the hemodynamic variables were measured in order to determine the maximal short-term effect of inhaled iloprost and the timing of the hemodynamic response.

All patients started treatment with a daily dose of 100 μg of aerosolized iloprost, divided into six or eight inhalations given every two to three hours, without interruption of bed rest at night. Since pharmacokinetic studies of aerosolized iloprost were not available when treatment was started, the daily dose was adapted from the initial report by Olschewski et al.9 The dosage per inhalation and the inhalation interval were determined on the basis of information gained from pulmonary-artery catheter testing at base line. If the pulmonary vascular resistance fell by more than 20 percent after the inhalation of iloprost but returned to base line within less than 60 minutes, the patient was asked to inhale eight times per day. All other patients inhaled six times per day. The dose was increased to 150 μg in six patients after three months.

After familiarization with the equipment, the patients were discharged and were seen every 4 to 12 weeks on an outpatient basis. Readmissions were scheduled after 3 to 12 months for the determination of exercise capacity and repeated right-heart catheterization. The six-minute walk tests during follow-up were performed more than one hour after the last inhalation. All six-minute walk tests were performed over the same route. The catheter tests started early in the morning before the first inhalation of iloprost — that is, between 10 and 12 hours after the last inhalation of iloprost — and the same protocol was used as for the base-line evaluation.

Statistical Analysis

All hemodynamic variables and the results of the six-minute walk test are presented as means ±SD. The short-term hemodynamic effects of iloprost challenge were analyzed with Student's paired t-test. The results of the six-minute walk tests and the hemodynamic variables at base line and after 3 and 12 months of treatment with inhaled iloprost were compared by analysis of variance for repeated measurements. If this global test revealed significant differences, the paired t-test was applied to differences between specific groups. Patients who were unable to walk were assigned a score of 0 m on the six-minute walk test. Statistical comparisons of the hemodynamic variables were performed only for the data obtained before the inhalation of iloprost (preinhalation values). Linear regression analysis was used to compare the short-term changes in pulmonary vascular resistance in response to inhaled iloprost at base line with the changes after 12 months of treatment.16 All tests were two-sided. A P value of less than 0.05 was considered to indicate statistical significance.

Results

Between March 1997 and June 1998, treatment with aerosolized iloprost was initiated in 31 patients with primary pulmonary hypertension. None of the patients died within the observation period. Seven patients were excluded from the analysis because follow-up examinations were performed at other centers or by other physicians. The remaining 24 patients received treatment with aerosolized iloprost for at least one year and completed exercise-testing and catheter studies. Fifteen of these patients were women and nine were men. The mean age was 38±12 years (range, 22 to 65). As shown in Table 1Table 1Hemodynamic Variables and Exercise Capacity in 24 Patients with Primary Pulmonary Hypertension Treated with Inhaled Iloprost., all 24 patients had severe pulmonary hypertension and were in New York Heart Association functional class III (20 patients) or IV (4 patients).

The initial daily dose of aerosolized iloprost was 100 μg in all patients. This dose was subsequently increased to 150 μg in six patients whose exercise capacity did not improve after three months of treatment. In the remaining patients, the dose was kept constant throughout the observation period. All patients received anticoagulants. Diuretics were used as clinically indicated. Patients receiving concomitant treatment with digitalis or calcium-channel blockers continued the treatment during the observation period.

As shown in Table 1, results of the six-minute walk test confirmed the presence of severe functional impairment at base line. The distance covered in this test increased significantly, by 75±67 m, after three months of treatment with aerosolized iloprost (P< 0.001). This effect was sustained after 12 months, but there was no further significant increase in the walking distance as compared with the results at 3 months.

Challenge with inhaled iloprost caused a short-term decline of 9±9.2 mm Hg in mean pulmonary arterial pressure (mean change, –15 percent [the negative value indicates a decrease]; P<0.001), accompanied by an increase in cardiac output of 0.7±0.5 liter per minute (mean change, +18 percent; P< 0.001) and a reduction in pulmonary vascular resistance of 339±260 dynseccm^–5 (mean change, –28 percent; P<0.001) (Table 1). The heart rate and systemic arterial pressure remained practically unaffected. Almost identical short-term hemodynamic effects were obtained with repeated iloprost challenge after 3 and 12 months (Table 1).

As compared with base line, after three months of treatment with aerosolized iloprost there was significant improvement in the values before the inhalation of iloprost for mean pulmonary arterial pressure, mean right atrial pressure, pulmonary vascular resistance, stroke volume, and mixed venous oxygen saturation (Table 1). These effects were sustained at 12 months. At this time, there was also a significant increase in cardiac output as compared with base line, suggesting effective improvement in right ventricular performance with long-term administration of aerosolized iloprost. As compared with base line, preinhalation mean pulmonary arterial pressure was reduced by 7±8.7 mm Hg after 12 months of treatment (mean change, –12 percent; P=0.006), pulmonary vascular resistance by 280±323 dynseccm^–5 (mean change, –23 percent; P<0.001), and mean right atrial pressure by 3±4 mm Hg (P=0.01). In addition, preinhalation cardiac output increased by 0.6±1.3 liter per minute (mean change, +16 percent; P=0.02), heart rate remained nearly constant, stroke volume rose by 9±16 ml (mean change, +20 percent; P=0.009), and mixed venous oxygen saturation increased by 5±8 percentage points (mean change, +8 percent; P= 0.01) (Table 1). Thirteen of the 24 patients (54 percent) had a long-term reduction of at least 20 percent in preinhalation pulmonary vascular resistance (Figure 1Figure 1Pulmonary Vascular Resistance at Base Line and after 3 Months and 12 Months of Treatment with Aerosolized Iloprost.). At all times, there was further improvement in these variables immediately after the inhalation of iloprost (Table 1).

To assess the value of short-term drug challenge with inhaled iloprost for predicting the response to long-term treatment, we compared the short-term changes in pulmonary vascular resistance after inhalation of iloprost at base line with the effects of treatment with aerosolized iloprost on preinhalation pulmonary vascular resistance after 12 months (Figure 2Figure 2Regression Analysis of Short-Term Changes in Pulmonary Vascular Resistance in Response to Inhaled Iloprost at Base Line and Changes in Preinhalation Pulmonary Vascular Resistance after 12 Months of Treatment with Aerosolized Iloprost.). In general, patients with a more pronounced short-term response to inhaled iloprost were more likely to have a sustained long-term reduction in pulmonary vascular resistance (r=0.66, P<0.001). However, of the 12 patients in whom the pulmonary vascular resistance dropped by less than 20 percent during short-term drug challenge, 7 had sustained reductions in pulmonary vascular resistance after 12 months of treatment, whereas 1 patient had stable hemodynamic variables and the remaining 4 patients had increased levels of pulmonary vascular resistance, indicating worsening pulmonary hypertension (Figure 2). Two of the latter patients were eventually switched to continuous intravenous iloprost but did not have clinical improvement; they are currently awaiting lung transplantation.

Treatment with aerosolized iloprost was tolerated well by all patients. Coughing during inhalation was common during the first days of treatment but invariably disappeared spontaneously within the first four weeks. Lung function remained stable in all patients throughout the observation period, as did blood counts, serum electrolyte concentrations, creatinine concentrations, and the results of liver-function tests (data not shown). Five patients reported flushing, headache, and jaw pain at the end of the inhalation, but all of these side effects were rated as mild, and specific treatment or discontinuation of iloprost was not required. Gastrointestinal problems were not reported. Hemodynamic studies revealed a significant decline in systemic arterial pressure and systemic vascular resistance (Table 1), but symptomatic hypotension did not occur in any of the patients. In addition, there were no symptoms, such as dizziness or syncope, suggesting that no rebound phenomena occurred between inhalations or overnight. However, almost all patients described some fluctuations in their exercise capacity, which was usually highest immediately after inhalation and then slowly deteriorated over the following two to three hours until the next inhalation.

Discussion

Our data show that long-term treatment with aerosolized iloprost has beneficial effects on exercise capacity and hemodynamic variables in patients with primary pulmonary hypertension. The therapeutic efficacy of intravenous epoprostenol in primary pulmonary hypertension has been well described, but the mechanisms by which prostacyclin influences the course of the disease are incompletely understood. Several studies have shown that the long-term effects of epoprostenol in pulmonary hypertension go beyond vasodilation. Other factors involved may include antithrombotic and antiproliferative effects as well as modulating effects on growth factors and vascular remodeling.4,7,8,17-19 Some of these effects, such as inhibition of platelet aggregation, could outlast the presence of prostaglandins. In the case of inhaled iloprost, however, it is not yet clear whether plasma concentrations reach sufficient levels to exert an effect on platelet function.

In addition, it is unknown whether prostaglandins need to be administered continuously to exert their therapeutic effect in patients with pulmonary hypertension. The answer to this question, however, is essential for deciding whether to use aerosolized iloprost as an alternative treatment in these patients. Even if the plasma half-life of iloprost is 20 to 30 minutes,8 the short-term hemodynamic effects of a single inhaled dose almost invariably disappear within an hour after inhalation.11 Therefore, our observation of improved preinhalation hemodynamic variables (measured after an overnight break in inhalation therapy) after one year of treatment with aerosolized iloprost suggests that mechanisms other than vasodilation contribute to its therapeutic effects. Our findings that the short-term vasodilator response to inhaled iloprost is preserved after 12 months of treatment and that the postinhalation reduction in pulmonary vascular resistance after 12 months exceeded the short-term hemodynamic effects at base line further support this conclusion.

The advantage of inhaled prostanoids over intravenous epoprostenol is that they do not require insertion of a permanent central venous catheter. The main question is whether inhaled iloprost is as effective as intravenous epoprostenol in improving exercise capacity and reducing mortality among patients with primary pulmonary hypertension. Despite the fact that intravenous epoprostenol has been used for more than 10 years to treat pulmonary hypertension, surprisingly little information is available on its long-term effects in this disease. McLaughlin et al. recently described their experience with long-term intravenous epoprostenol therapy in 27 patients with primary pulmonary hypertension.7 Drug challenge with intravenous adenosine had short-term hemodynamic effects similar to those of inhaled iloprost in our patients. McLaughlin et al. reported a reduction of 53 percent in pulmonary vascular resistance after 12 to 24 months of treatment with intravenous epoprostenol, which clearly exceeded the 23 percent reduction in preinhalation pulmonary vascular resistance in our patients after 1 year of treatment with iloprost aerosol. However, in our patients the postinhalation pulmonary vascular resistance after one year of treatment was reduced by 42 percent from the base-line preinhalation value, a reduction close to that obtained with intravenous epoprostenol in the study by McLaughlin et al.

The dose of aerosolized iloprost was kept constant at 100 μg per day in the majority of our patients; it was increased to 150 μg per day in six patients whose response was judged unsatisfactory. We do not know, however, whether the regimen we used had optimal efficacy or whether higher doses, different inhalation intervals, or a regimen including regular dose increases would have been better. In the study by McLaughlin et al., the dose of intravenous epoprostenol was increased by an average of 2.4 ng per kilogram of body weight per minute each month, which resulted in a mean dose of approximately 40 ng per kilogram of body weight per minute after 12 to 24 months of treatment.7 In Germany the annual cost of treating a patient with intravenous epoprostenol at this dose would exceed $300,000. With the inhalation device used in our hospital, the annual cost of treatment with aerosolized iloprost is about $50,000 for a daily dose of 100 μg and $75,000 for a daily dose of 150 μg. With newly developed ultrasonic nebulizers, these costs can be reduced by almost 50 percent.20

Inhaled iloprost was generally well tolerated, and no patient discontinued treatment because of side effects. The occurrence of jaw pain and flushing in some patients, as well as a significant, albeit asymptomatic, decline in systemic arterial pressure, suggests that aerosolized iloprost is not a purely selective pulmonary vasodilator, but, rather, that there is some systemic spillover of the drug. There are further unresolved issues regarding the safety of inhaled iloprost. Among these, the possibility of rebound pulmonary hypertension between inhalations and after the overnight break in inhalation therapy is of great concern. However, in our patients there were no clinical or hemodynamic signs of rebound pulmonary hypertension. Rebound phenomena have been recognized as a potentially life-threatening complication in patients receiving intravenous epoprostenol with short-term interruptions of drug delivery.21 Still, almost all our patients described some fluctuations in their exercise capacity between inhalations. These fluctuations were well tolerated by our patients but could be detrimental in patients with advanced right heart failure. We also found that 5 of the 24 patients (21 percent) had no clinical response to treatment with aerosolized iloprost; it is unclear whether these patients would benefit from a further increase in the dose of inhaled iloprost or whether they should be switched to intravenous epoprostenol.

Overall, our data support the conclusion that aerosolized iloprost is an effective treatment for primary pulmonary hypertension. Currently, phase 3 studies are under way in Europe that are expected to result in the licensing of inhaled iloprost for the treatment of pulmonary hypertension. With this approach, the options for therapy in advanced pulmonary hypertension increase, but so do the uncertainties about the optimal first-line treatment of patients with this condition. The time has come for studies comparing the long-term effects of intravenous epoprostenol and aerosolized iloprost in patients with primary pulmonary hypertension.

Source Information

From the Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany.

Address reprint requests to Dr. Hoeper at the Department of Respiratory Medicine, Hannover Medical School, 30623 Hannover, Germany, or at kmhoeper@aol.com.

References

References

1. 1

   Higenbottam TW, Wheeldon D, Wells F, Wallwork J. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet 1984;1:1046-1047
   CrossRef | Web of Science | Medline

2. 2

   Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): results of a randomized trial. Ann Intern Med 1990;112:485-491
   Web of Science | Medline

3. 3

   Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994;121:409-415
   Web of Science | Medline

4. 4

   Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296-301
   Full Text | Web of Science | Medline

5. 5

   Shapiro SM, Oudiz RJ, Cao T, et al. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 1997;30:343-349
   CrossRef | Web of Science | Medline

6. 6

   Hinderliter AL, Willis PW IV, Barst RJ, et al. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Circulation 1997;95:1479-1486
   Web of Science | Medline

7. 7

   McLaughlin VV, Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998;338:273-277
   Full Text | Web of Science | Medline

8. 8

   Grant SM, Goa KL. Iloprost: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures. Drugs 1992;43:889-924
   CrossRef | Web of Science | Medline

9. 9

   Olschewski H, Walmrath D, Schermuly R, Ghofrani A, Grimminger F, Seeger W. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 1996;124:820-824
   Web of Science | Medline

10. 10

    Olschewski H, Ghofrani HA, Schmehl T, et al. Inhaled iloprost to treat severe pulmonary hypertension: an uncontrolled trial. Ann Intern Med 2000;132:435-443
    Web of Science | Medline

11. 11

    Hoeper MM, Olschewski H, Ghofrani HA, et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. J Am Coll Cardiol 2000;35:176-182
    CrossRef | Web of Science | Medline

12. 12

    Olschewski H, Ghofrani HA, Walmrath D, et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 1999;160:600-607
    Web of Science | Medline

13. 13

    Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987;107:216-223
    Web of Science | Medline

14. 14

    Guyatt GH, Sullivan MJ, Thompson PJ, et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. CMAJ 1985;132:919-923
    Web of Science | Medline

15. 15

    Hoeper MM, Maier R, Tongers J, et al. Determination of cardiac output by the Fick method, thermodilution, and acetylene rebreathing in pulmonary hypertension. Am J Respir Crit Care Med 1999;160:535-541
    Web of Science | Medline

16. 16

    Rosner B. Fundamentals of biostatistics. 4th ed. Belmont, Calif.: Duxbury Press, 1995.
    

17. 17

    Hoeper MM, Voelkel NF, Bates TO, et al. Prostaglandins induce vascular endothelial growth factor in a human monocytic cell line and rat lungs via cAMP. Am J Respir Cell Mol Biol 1997;17:748-756
    Web of Science | Medline

18. 18

    Fishman AP. Pulmonary hypertension -- beyond vasodilator therapy. N Engl J Med 1998;338:321-322
    Full Text | Web of Science | Medline

19. 19

    Fishman AP. Epoprostenol (prostacyclin) and pulmonary hypertension. Ann Intern Med 2000;132:500-502
    Web of Science | Medline

20. 20

    Gessler T, Schmehl T, Seeger W. Comparison of two inhalation systems for Ilomedin-aerosol therapy in pulmonary hypertension. Am J Respir Crit Care Med 1999;159:Suppl:A159-A159 abstract.
    Web of Science

21. 21

    Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997;336:111-117
    Full Text | Web of Science | Medline

Citing Articles (153)

Citing Articles

1. 1

   Cécile Tissot, Maurice Beghetti. 2012. Pediatric Pulmonary Hypertension. , 730-752.
   CrossRef

2. 2

   Minh Thanh Bui, Oswin Grollmus, Mohamedou Ly, Anca Mandache, Elie Fadel, Benoit Decante, Alain Serraf. (2011) Surgical palliation of primary pulmonary arterial hypertension by a unidirectional valved Potts anastomosis in an animal model. The Journal of Thoracic and Cardiovascular Surgery 142:5, 1223-1228
   CrossRef

3. 3

   Peter Oishi, Sanjeev A Datar, Jeffrey R Fineman. (2011) Pediatric pulmonary arterial hypertension: current and emerging therapeutic options. Expert Opinion on Pharmacotherapy 12:12, 1845-1864
   CrossRef

4. 4

   Johann Strumpher, Eric Jacobsohn. (2011) Pulmonary Hypertension and Right Ventricular Dysfunction: Physiology and Perioperative Management. Journal of Cardiothoracic and Vascular Anesthesia 25:4, 687-704
   CrossRef

5. 5

   Yannis Hara, Yassine Sassi, Christelle Guibert, Natacha Gambaryan, Peter Dorfmüller, Saadia Eddahibi, Anne-Marie Lompré, Marc Humbert, Jean-Sébastien Hulot. (2011) Inhibition of MRP4 prevents and reverses pulmonary hypertension in mice. Journal of Clinical Investigation 121:7, 2888-2897
   CrossRef

6. 6

   Zeenat Safdar. (2011) Treatment of pulmonary arterial hypertension: The role of prostacyclin and prostaglandin analogs. Respiratory Medicine 105:6, 818-827
   CrossRef

7. 7

   Ralf Ewert, Sven Gläser, Tom Bollmann, Christoph Schäper. (2011) Inhaled iloprost for therapy in pulmonary arterial hypertension. Expert Review of Respiratory Medicine 5:2, 145-152
   CrossRef

8. 8

   Myrna B Dolovich, Rajiv Dhand. (2011) Aerosol drug delivery: developments in device design and clinical use. The Lancet 377:9770, 1032-1045
   CrossRef

9. 9

   Julie John, Harold Palevsky. (2011) Clinical pharmacology and efficacy of inhaled iloprost for the treatment of pulmonary arterial hypertension. Expert Review of Clinical Pharmacology 4:2, 197-205
   CrossRef

10. 10

    Frank Reichenberger, Ann Mainwood, Nicholas W. Morrell, Jayan Parameshwar, Joanna Pepke-Zaba. (2011) Intravenous epoprostenol versus high dose inhaled iloprost for long-term treatment of pulmonary hypertension. Pulmonary Pharmacology & Therapeutics 24:1, 169-173
    CrossRef

11. 11

    Peter Oishi, Julien I.E. Hoffman, Bradley P. Fuhrman, Jeffrey R. Fineman. 2011. Regional Circulation. , 217-233.
    CrossRef

12. 12

    Satyan Lakshminrusimha, Vasanth H. Kumar. 2011. Diseases of Pulmonary Circulation. , 632-656.
    CrossRef

13. 13

    Shuang Zhang, Yun Liu, Shouli Guo, Jianing Zhang, Xiaojie Chu, Chun Jiang, Daling Zhu. (2010) Vasoactive intestinal polypeptide relaxes isolated rat pulmonary artery rings through two distinct mechanisms. The Journal of Physiological Sciences 60:6, 389-397
    CrossRef

14. 14

    Hatem Alameri, Yusra Al-Kabab, Ahmed BaHammam. (2010) Submaximal exercise in patients with severe obstructive sleep apnea. Sleep and Breathing 14:2, 145-151
    CrossRef

15. 15

    Dimitar Sajkov, Nikolai Petrovsky, Paolo Palange. (2010) Management of dyspnea in advanced pulmonary arterial hypertension. Current Opinion in Supportive and Palliative Care 4:2, 76-84
    CrossRef

16. 16

    Joe R. Anderson, James J. Nawarskas. (2010) Pharmacotherapeutic Management of Pulmonary Arterial Hypertension. Cardiology in Review 18:3, 148-162
    CrossRef

17. 17

    D. Dunbar Ivy. (2010) Prostacyclin in the intensive care setting. Pediatric Critical Care Medicine 11, S41-S45
    CrossRef

18. 18

    Steven H. Abman. (2010) Pulmonary hypertension in children: A historical overview. Pediatric Critical Care Medicine 11, S4-S9
    CrossRef

19. 19

    Khaled Abdelhady, Patricia Gramling-Babb, Sawsan Awad, Abdallah G Rebeiz, Payam Salehi, Ahmad Chaudhry, Michael Diodato, Lona Ernst Rizkallah, Edgar G Chedrawy, Sunil Prasad, Malek G Massad. (2010) Current and future therapy for pulmonary hypertension in patients with right and left heart failure. Expert Review of Cardiovascular Therapy 8:2, 241-250
    CrossRef

20. 20

    Monnipa Suesaowalak, John P. Cleary, Anthony C. Chang. (2010) Advances in diagnosis and treatment of pulmonary arterial hypertension in neonates and children with congenital heart disease. World Journal of Pediatrics 6:1, 13-31
    CrossRef

21. 21

    TOMMI NOPONEN, ANDERS NORDH, ANSGAR BERG, DAVID LEY, STEFAN R. HANSSON, ERKKI PESONEN, VINETA FELLMAN. (2009) Circulatory Effects of Inhaled Iloprost in the Newborn Preterm Lamb. Pediatric Research 66:4, 416-422
    CrossRef

22. 22

    Geoff STRANGE, Peter NASH. (2009) The manifestations of vasculopathy in systemic sclerosis and its evidence-based therapy. International Journal of Rheumatic Diseases 12:3, 192-206
    CrossRef

23. 23

    Cecile Tissot, Maurice Beghetti. (2009) Advances in therapies for pediatric pulmonary arterial hypertension. Expert Review of Respiratory Medicine 3:3, 265-282
    CrossRef

24. 24

    Scott Gleim, Zsolt Kasza, Kathleen Martin, John Hwa. (2009) Prostacyclin receptor/thromboxane receptor interactions and cellular responses in human atherothrombotic disease. Current Atherosclerosis Reports 11:3, 227-235
    CrossRef

25. 25

    Robyn J. Barst, Duncan Stewart. (2009) Conventional and targeted medical therapies. Cardiology in the Young 19:S1, 28
    CrossRef

26. 26

    Vallerie V. McLaughlin, Stephen L. Archer, David B. Badesch, Robyn J. Barst, Harrison W. Farber, Jonathan R. Lindner, Michael A. Mathier, Michael D. McGoon, Myung H. Park, Robert S. Rosenson, Lewis J. Rubin, Victor F. Tapson, John Varga. (2009) ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. Journal of the American College of Cardiology 53:17, 1573-1619
    CrossRef

27. 27

    Tanja Johannes, Can Ince, Karin Klingel, Klaus E. Unertl, Egbert G. Mik. (2009) Iloprost preserves renal oxygenation and restores kidney function in endotoxemia-related acute renal failure in the rat. Critical Care Medicine 37:4, 1423-1432
    CrossRef

28. 28

    M. D. McGoon, G. C. Kane. (2009) Pulmonary Hypertension: Diagnosis and Management. Mayo Clinic Proceedings 84:2, 191-207
    CrossRef

29. 29

    Justin S. W. Taylor, Julian P. J. Halcox. (2008) PDE5 inhibitors and pulmonary hypertension. Current Sexual Health Reports 5:4, 171-178
    CrossRef

30. 30

    Ralf Ewert, Sven Gläser, Christian Opitz. (2008) Iloprost in pulmonary hypertension. Expert Review of Respiratory Medicine 2:6, 689-702
    CrossRef

31. 31

    J. Sánchez Román, F.J. García Hernández, M.J. Castillo Palma, R. González León. (2008) Tratamiento de la hipertensión arterial pulmonar. Estrategias terapéuticas. Fármacos. Criterios de empleo. Indicaciones. Contraindicaciones. Posología. Efectos secundarios. Criterios de asociación y sustitución. Medicine - Programa de Formación Médica Continuada Acreditado 10:23, 1566-1574
    CrossRef

32. 32

    Robert Voswinckel, Frank Reichenberger, Beate Enke, Andre Kreckel, Stefanie Krick, Henning Gall, Ralph Theo Schermuly, Friedrich Grimminger, Lewis J. Rubin, Horst Olschewski, Werner Seeger, Hossein A. Ghofrani. (2008) Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension. Pulmonary Pharmacology & Therapeutics 21:5, 824-832
    CrossRef

33. 33

    Madhavi T. Reddy, Hamang Patel, Hector O. Ventura. (2008) Successful Transition From Intravenous to Inhaled Prostacyclin in a Patient With Pulmonary Hypertension and Right Ventricular Failure. Congestive Heart Failure 14:5, 285-286
    CrossRef

34. 34

    Tobias Gessler, Werner Seeger, Thomas Schmehl. (2008) Inhaled Prostanoids in the Therapy of Pulmonary Hypertension. Journal of Aerosol Medicine and Pulmonary Drug Delivery 21:1, 1-12
    CrossRef

35. 35

    Tobias Gessler, Werner Seeger, Thomas Schmehl. (2008) Inhaled Prostanoids in the Therapy of Pulmonary Hypertension. Journal of Aerosol Medicine 0:0, 080116123756336-12
    CrossRef

36. 36

    James A Driscoll, Murali M Chakinala. (2008) Medical therapy for pulmonary arterial hypertension. Expert Opinion on Pharmacotherapy 9:1, 65-81
    CrossRef

37. 37

    Mardi Gomberg-Maitland, Thenappan Thenappan, Kamran Rizvi, Sonal Chandra, David M. Meads, Stephen P. McKenna. (2008) United States Validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR). The Journal of Heart and Lung Transplantation 27:1, 124-130
    CrossRef

38. 38

    S. REX, G. SCHAELTE, S. METZELDER, S. FLIER, E. E. C. DE WAAL, R. AUTSCHBACH, R. ROSSAINT, W. BUHRE. (2008) Inhaled iloprost to control pulmonary artery hypertension in patients undergoing mitral valve surgery: a prospective, randomized-controlled trial. Acta Anaesthesiologica Scandinavica 52:1, 65-72
    CrossRef

39. 39

    Mehmet Emin Ozdogan, Dilek Erer, Erkan Iriz, Gursel Levent Oktar, Serdar Kula, Mustafa Buyukates. (2008) Right-to-left Shunt Through a Patent Foramen Ovale Left Open in the Management of Acute Right Heart Failure After Heart Transplantation. The Journal of Heart and Lung Transplantation 27:1, 135-137
    CrossRef

40. 40

    Robert Naeije, Sandrine Huez. (2007) Expert opinion on available options treating pulmonary arterial hypertension. Expert Opinion on Pharmacotherapy 8:14, 2247-2265
    CrossRef

41. 41

    Neal Benedict, Amy Seybert, Michael A. Mathier. (2007) Evidence-Based Pharmacologic Management of Pulmonary Arterial Hypertension. Clinical Therapeutics 29:10, 2134-2153
    CrossRef

42. 42

    Melvyn Rubenfire, Melike Bayram, Zachary Hector-Word. (2007) Pulmonary Hypertension in the Critical Care Setting: Classification, Pathophysiology, Diagnosis, and Management. Critical Care Clinics 23:4, 801-834
    CrossRef

43. 43

    Roham T. Zamanian, Francois Haddad, Ramona L. Doyle, Ann B. Weinacker. (2007) Management strategies for patients with pulmonary hypertension in the intensive care unit*. Critical Care Medicine 35:9, 2037-2050
    CrossRef

44. 44

    Tomas Bratel, Lars Lagerstrand, Lars-Åke Brodin, Jacek Nowak, Ivar Randmaa. (2007) Ventilation–perfusion relationships in pulmonary arterial hypertension: Effect of intravenous and inhaled prostacyclin treatment. Respiratory Physiology & Neurobiology 158:1, 59-69
    CrossRef

45. 45

    Pasquale Chitano, Lu Wang, Thomas M. Murphy. (2007) Three paradigms of airway smooth muscle hyperresponsiveness in young guinea pigsThis article is one of a selection of papers published in the Special Issue on Recent Advances in Asthma Research.. Canadian Journal of Physiology and Pharmacology 85:7, 715-726
    CrossRef

46. 46

    Aniket Puri, Michael D McGoon, Sudhir S Kushwaha. (2007) Pulmonary arterial hypertension: current therapeutic strategies. Nature Clinical Practice Cardiovascular Medicine 4:6, 319-329
    CrossRef

47. 47

    H. Schotte, H. Becker, P. Willeke, M. A. Schorat, W. Domschke, M. Gaubitz. (2007) Screening for pulmonary arterial hypertension in patients with systemic rheumatic diseases. Current Medical Research and Opinion 23:s2, S43-S47
    CrossRef

48. 48

    Nazzareno Galiè, Naushad Hirani, Alessandra Manes, Serena Romanazzi, Massimiliano Palazzini, Luca Negro, Angelo Branzi. (2007) Long-term therapeutic outcomes in pulmonary arterial hypertension. Current Medical Research and Opinion 23:s2, S11-S18
    CrossRef

49. 49

    Ralf Ewert, Christian F. Opitz, Roland Wensel, Jörg Winkler, Michael Halank, Stephan B. Felix. (2007) Continuous intravenous iloprost to revert treatment failure of first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Clinical Research in Cardiology 96:4, 211-217
    CrossRef

50. 50

    Wayne L. Strauss, Jeffrey D. Edelman. (2007) Prostanoid Therapy for Pulmonary Arterial Hypertension. Clinics in Chest Medicine 28:1, 127-142
    CrossRef

51. 51

    Adolfo Baloira. (2007) Futuro del tratamiento de la hipertensión pulmonar. Archivos de Bronconeumología 43:3, 131-135
    CrossRef

52. 52

    Shoaib Alam, Harold I. Palevsky. (2007) Standard Therapies for Pulmonary Arterial Hypertension. Clinics in Chest Medicine 28:1, 91-115
    CrossRef

53. 53

    Ana Oliveira, Daniela Ferreira, António Caiado, Susana Ferreira, Paula Ferreira, Lino Santos, Manuel Gonçalves, Teresa Shiang, Bárbara Parente, Rosas Vieira, Vasco Gama Ribeiro. (2007) Hipertensão arterial pulmonar – Experiência do Centro Hospitalar de Vila Nova de Gaia. Revista Portuguesa de Pneumologia (English Edition) 13:2, 239-254
    CrossRef

54. 54

    Rajiv Dhand. (2007) Inhalation therapy in invasive and noninvasive mechanical ventilation. Current Opinion in Critical Care 13:1, 27-38
    CrossRef

55. 55

    Marco Idzko, Hamida Hammad, Menno van Nimwegen, Mirjam Kool, Nanda Vos, Henk C. Hoogsteden, Bart N. Lambrecht. (2007) Inhaled iloprost suppresses the cardinal features of asthma via inhibition of airway dendritic cell function. Journal of Clinical Investigation 117:2, 464-472
    CrossRef

56. 56

    F. Reichenberger, A. Mainwood, N. Doughty, A. Fineberg, N.W. Morrell, J. Pepke-Zaba. (2007) Effects of nebulised iloprost on pulmonary function and gas exchange in severe pulmonary hypertension. Respiratory Medicine 101:2, 217-222
    CrossRef

57. 57

    Derliz Mereles, Ralf Ewert, Sven Lodziewski, Mathias M. Borst, Andreas Benz, Horst Olschewski, Ekkehard Gr&uuml;nig. (2007) Effect of Inhaled Iloprost during Off-Medication Time in Patients with Pulmonary Arterial Hypertension. Respiration 74:5, 498-502
    CrossRef

58. 58

    Rajiv Dhand, Emmanuelle Mercier. (2007) Effective inhaled drug administration to mechanically ventilated patients. Expert Opinion on Drug Delivery 4:1, 47-61
    CrossRef

59. 59

    Joern Tongers, Ben Schwerdtfeger, Gunnar Klein, Tibor Kempf, Arnd Schaefer, Julia-Marie Knapp, Michael Niehaus, Thomas Korte, Marius M. Hoeper. (2007) Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension. American Heart Journal 153:1, 127-132
    CrossRef

60. 60

    Erika B Rosenzweig. (2006) Emerging treatments for pulmonary arterial hypertension. Expert Opinion on Emerging Drugs 11:4, 609-619
    CrossRef

61. 61

    Fuat H. Saner, Silvio Nadalin, Goran Pavlakovi??, Yanli Gu, Steven W. M. Olde Damink, Julia Gensicke, Nils R. Fruhauf, Andreas Paul, Arnold Radtke, Georgios C. Sotiropoulos, Massimo Malag??, Christoph E. Broelsch. (2006) Portopulmonary Hypertension in the Early Phase Following Liver Transplantation. Transplantation 82:7, 887-891
    CrossRef

62. 62

    Stephen L Archer, Evangelos D Michelakis. (2006) An evidence-based approach to the management of pulmonary arterial hypertension. Current Opinion in Internal Medicine 5:5, 453-460
    CrossRef

63. 63

    Son-Mi Chung, Chang-Keun Lee, Eun Young Lee, Bin Yoo, Sang-Do Lee, Hee-Bom Moon. (2006) Clinical aspects of pulmonary hypertension in patients with systemic lupus erythematosus and in patients with idiopathic pulmonary arterial hypertension. Clinical Rheumatology 25:6, 866-872
    CrossRef

64. 64

    Sabina A Antoniu. (2006) Sildenafil for pulmonary arterial hypertension: when blue turns into white. Expert Opinion on Pharmacotherapy 7:13, 1801-1810
    CrossRef

65. 65

    V. V. McLaughlin. (2006) Survival in patients with pulmonary arterial hypertension treated with first-line bosentan. European Journal of Clinical Investigation 36:s3, 10-15
    CrossRef

66. 66

    Ralph Theo Schermuly, Andreas Schulz, Hossein Ardeschir Ghofrani, Christina Susanne Breitenbach, Norbert Weissmann, Michael Hildebrand, Julia Kurz, Friedrich Grimminger, Werner Seeger. (2006) Comparison of Pharmacokinetics and Vasodilatory Effect of Nebulized and Infused Iloprost in Experimental Pulmonary Hypertension: Rapid Tolerance Development. Journal of Aerosol Medicine 19:3, 353-363
    CrossRef

67. 67

    F. Cozzi, R. Montisci, H. Marotta, F. Bobbo, N. Durigon, M. Ruscazio, P. Sfriso, S. Iliceto, S. Todesco. (2006) Bosentan therapy of pulmonary arterial hypertension in connective tissue diseases. European Journal of Clinical Investigation 36:s3, 49-53
    CrossRef

68. 68

    M. Beghetti. (2006) Current treatment options in children with pulmonary arterial hypertension and experiences with oral bosentan. European Journal of Clinical Investigation 36:s3, 16-24
    CrossRef

69. 69

    Maria E. Campian, Maxim Hardziyenka, Martin C. Michel, Hanno L. Tan. (2006) How valid are animal models to evaluate treatments for pulmonary hypertension?. Naunyn-Schmiedeberg's Archives of Pharmacology 373:6, 391-400
    CrossRef

70. 70

    So-Yeon Park, Dae-Hyuk Moon, Yong-Bum Park, Ju-Ok Na, Heong-Kon Whang, Byoung-Sung Lim, Sang-Do Lee. (2006) Perfusion lung scan as a prognostic indicator of response to beraprost sodium in idiopathic pulmonary arterial hypertension. Pulmonary Pharmacology & Therapeutics 19:4, 264-271
    CrossRef

71. 71

    ANDY J. PETROS, CHRISTINE M. PIERCE. (2006) The management of pulmonary hypertension. Pediatric Anesthesia 0:0, 060706013023002-???
    CrossRef

72. 72

    Michael A. Ramsay. (2006) Portopulmonary Hypertension and Hepatopulmonary Syndrome, and Liver Transplantation. International Anesthesiology Clinics 44:3, 69-82
    CrossRef

73. 73

    Eric D. Morrell, Ben M. Tsai, Paul R. Crisostomo, Zane T. Hammoud, Daniel R. Meldrum. (2006) EXPERIMENTAL THERAPIES FOR HYPOXIA-INDUCED PULMONARY HYPERTENSION DURING ACUTE LUNG INJURY. Shock 25:3, 214-226
    CrossRef

74. 74

    Christine Archer-Chicko, Traci Housten-Harris, Harold I. Palevsky. 2006. Practical Nursing Issues in the Outpatient Management of Pulmonary Vascular Disease. , 314-329.
    CrossRef

75. 75

    Erika Berman Rosenzweig, Robyn J Barst. (2006) Pulmonary Arterial Hypertension. Treatments in Respiratory Medicine 5:2, 117-127
    CrossRef

76. 76

    Anna M. Hackman, Thomas E. Lackner. (2006) Pharmacotherapy for Idiopathic Pulmonary Arterial Hypertension During the Past 25 Years. Pharmacotherapy 26:1, 68-94
    CrossRef

77. 77

    Judit Végh, Györgyike Soós, István Csipõ, Nóra Demeter, Thomas Ben, Balázs Dezsõ, Margit Zeher, Katalin Dévényi, János Gaál, Gyula Szegedi, Edit Bodolay. (2006) Pulmonary arterial hypertension in mixed connective tissue disease: successful treatment with Iloprost. Rheumatology International 26:3, 264-269
    CrossRef

78. 78

    Azad Raiesdana, Joseph Loscalzo. (2006) Pulmonary arterial hypertension. Annals of Medicine 38:2, 95-110
    CrossRef

79. 79

    2006. Prostaglandins. , 2955-2964.
    CrossRef

80. 80

    Arnaud Resten, Sophie Maitre, Dominique Musset. (2005) CT imaging of peripheral pulmonary vessel disease. European Radiology 15:10, 2045-2056
    CrossRef

81. 81

    Henry H Hsu, Lewis J Rubin. (2005) Iloprost inhalation solution for the treatment of pulmonary arterial hypertension. Expert Opinion on Pharmacotherapy 6:11, 1921-1930
    CrossRef

82. 82

    Brent D. Weinberg, Steven J. Schomisch, Muhib Rahmatalla, Warren H. Finlay, Ashutosh Chaturvedi, Greg R. Wojtkiewicz, Zhenghong Lee. (2005) Mapping of PET-measured aerosol deposition: a comparison study. Journal of Aerosol Science 36:9, 1157-1176
    CrossRef

83. 83

    Peter Germann, Antonio Braschi, Giorgio Della Rocca, Anh Tuan Dinh-Xuan, Konrad Falke, Claes Frostell, Lars E. Gustafsson, Philippe Hervé, Philippe Jolliet, Udo Kaisers, Hector Litvan, Duncan J. Macrae, Marco Maggiorini, Nandor Marczin, Bernd Mueller, Didier Payen, Marco Ranucci, Dietmar Schranz, Rainer Zimmermann, Roman Ullrich. (2005) Inhaled nitric oxide therapy in adults: European expert recommendations. Intensive Care Medicine 31:8, 1029-1041
    CrossRef

84. 84

    Erika Berman Rosenzweig, Robyn J Barst. (2005) Idiopathic pulmonary arterial hypertension in children. Current Opinion in Pediatrics 17:3, 372-380
    CrossRef

85. 85

    Friedrich M. Fruhwald, Barbro Kjellström, Wolfgang Perthold, Manfred Wonisch, Robert Maier, Werner Klein. (2005) Hemodynamic Observations in Two Pulmonary Hypertensive Patients Changing Treatment From Inhaled Iloprost to the Oral Endothelin-Antagonist Bosentan. The Journal of Heart and Lung Transplantation 24:5, 631-634
    CrossRef

86. 86

    Mohammed Najeeb Osman, Mark E. Dunlap. (2005) Management of heart failure with pulmonary hypertension. Current Cardiology Reports 7:3, 196-203
    CrossRef

87. 87

    (2005) Guías de Práctica Clínica sobre el diagnóstico y tratamiento de la hipertensión arterial pulmonar. Revista Española de Cardiología 58:5, 523-566
    CrossRef

88. 88

    N Shanthi Paramothayan, Toby J Lasserson, Athol Wells, E. Haydn Walters, N Shanthi Paramothayan. 2005. Prostacyclin for pulmonary hypertension in adults. .
    CrossRef

89. 89

    Hanno H Leuchte, Jürgen Behr. (2005) Iloprost for idiopathic pulmonary arterial hypertension. Expert Review of Cardiovascular Therapy 3:2, 215-223
    CrossRef

90. 90

    Darren B. Taichman, Harold I. Palevsky. (2005) Treatment of Pulmonary Arterial Hypertension With the Endothelin Receptor Antagonist Bosentan. Clinical Pulmonary Medicine 12:2, 121-127
    CrossRef

91. 91

    Michael Dandel, Hans B. Lehmkuhl, Roland Hetzer. (2005) Advances in the Medical Treatment of Pulmonary Hypertension. Kidney and Blood Pressure Research 28:5-6, 311-324
    CrossRef

92. 92

    G. Kemming, H. Kisch-Wedel, M. Flondor, C. Hofstetter, W. Kreyling, E. Thein, F. Meisner, S. Bruhn, B. Zwissler. (2005) Improved Ventricular Function during Inhalation of PGI₂ Aerosol Partly Relies on Enhanced Myocardial Contractility. European Surgical Research 37:1, 9-17
    CrossRef

93. 93

    Marius M Hoeper. (2005) Drug Treatment of Pulmonary Arterial Hypertension. Drugs 65:10, 1337-1354
    CrossRef

94. 94

    Abhijat Sheth, John E.S. Park, Yee Ean Ong, Timothy B. Ho, Brendan P. Madden. (2005) Early haemodynamic benefit of sildenafil in patients with coexisting chronic thromboembolic pulmonary hypertension and left ventricular dysfunction. Vascular Pharmacology 42:2, 41-45
    CrossRef

95. 95

    S. Barnes, B. Shields, W. Bonney, J. Hardin, R. Abdulla. (2004) The Pediatric Cardiology Pharmacopoeia: 2004 Update. Pediatric Cardiology 25:6, 623-646
    CrossRef

96. 96

    Noritoshi Nagaya, Kenji Kangawa. (2004) Adrenomedullin in the treatment of pulmonary hypertension. Peptides 25:11, 2013-2018
    CrossRef

97. 97

    D. Montani, X. Jaïs, V. Ioos, O. Sitbon, G. Simonneau, M. Humbert. (2004) Traitement de l'hypertension artérielle pulmonaire. La Revue de Médecine Interne 25:10, 720-731
    CrossRef

98. 98

    Anne Keogh, John Wlodarczyk. (2004) Idiopathic- and scleroderma-related pulmonary arterial hypertension: outcomes and QOL on bosentan. Expert Review of Pharmacoeconomics & Outcomes Research 4:5, 505-513
    CrossRef

99. 99

    Humbert, Marc, Sitbon, Olivier, Simonneau, Gérald, . (2004) Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine 351:14, 1425-1436
    Full Text

100. 100

     Pierre Tissières, Laurent Nicod, Constance Barazzone-Argiroffo, Peter C. Rimensberger, Maurice Beghetti. (2004) Aerosolized iloprost as a bridge to lung transplantation in a patient with cystic fibrosis and pulmonary hypertension. The Annals of Thoracic Surgery 78:3, e48-e50
     CrossRef

101. 101

     Yolanda Braun-Moscovici, A.Menahem Nahir, Alexandra Balbir-Gurman. (2004) Endothelin and pulmonary arterial hypertension. Seminars in Arthritis and Rheumatism 34:1, 442-453
     CrossRef

102. 102

     Ben M Tsai, Meijing Wang, Mark W Turrentine, Yousuf Mahomed, John W Brown, Daniel R Meldrum. (2004) Hypoxic pulmonary vasoconstriction in cardiothoracic surgery: basic mechanisms to potential therapies. The Annals of Thoracic Surgery 78:1, 360-368
     CrossRef

103. 103

     Erika Berman Rosenzweig, Allison C. Widlitz, Robyn J. Barst. (2004) Pulmonary arterial hypertension in children. Pediatric Pulmonology 38:1, 2-22
     CrossRef

104. 104

     David B Badesch, Vallerie V McLaughlin, Marion Delcroix, CarmineDario Vizza, Horst Olschewski, Olivier Sitbon, Robyn J Barst. (2004) Prostanoid therapy for pulmonary arterial hypertension. Journal of the American College of Cardiology 43:12, S56-S61
     CrossRef

105. 105

     Horst Olschewski, Frank Rose, Ralph Schermuly, H.Ardeschir Ghofrani, Beate Enke, Andrea Olschewski, Werner Seeger. (2004) Prostacyclin and its analogues in the treatment of pulmonary hypertension. Pharmacology & Therapeutics 102:2, 139-153
     CrossRef

106. 106

     Marius M Hoeper, Michael J Krowka, Christian P Strassburg. (2004) Portopulmonary hypertension and hepatopulmonary syndrome. The Lancet 363:9419, 1461-1468
     CrossRef

107. 107

     Kelly Chin, Richard Channick. (2004) Bosentan. Expert Review of Cardiovascular Therapy 2:2, 175-182
     CrossRef

108. 108

     Danny Chu, Christopher C Sullivan, Lingling Du, Augustine J Cho, Masakuni Kido, Paul L Wolf, Matthew D Weitzman, Stuart W Jamieson, Patricia A Thistlethwaite. (2004) A new animal model for pulmonary hypertension based on the overexpression of a single gene, angiopoietin-1. The Annals of Thoracic Surgery 77:2, 449-456
     CrossRef

109. 109

     David R Goldsmith, Antona J Wagstaff. (2004) Inhaled Iloprost. Drugs 64:7, 763-773
     CrossRef

110. 110

     H. Erhan Dincer, Kenneth W. Presberg. (2004) Current Management of Pulmonary Hypertension. Clinical Pulmonary Medicine 11:1, 40-53
     CrossRef

111. 111

     Dermot O'Callaghan, Sean P. Gaine. (2004) Bosentan: A novel agent for the treatment of pulmonary arterial hypertension. International Journal of Clinical Practice 58:1, 69-73
     CrossRef

112. 112

     Deborah H Markowitz, David M Systrom. (2004) Diagnosis of pulmonary vascular limit to exercise by cardiopulmonary exercise testing. The Journal of Heart and Lung Transplantation 23:1, 88-95
     CrossRef

113. 113

     Gilbert Blaise, David Langleben, Bernard Hubert. (2003) Pulmonary Arterial Hypertension. Anesthesiology 99:6, 1415-1432
     CrossRef

114. 114

     S. Bhatia, R. P. Frantz, C. J. Severson, L. A. Durst, M. D. McGoon. (2003) Immediate and Long-term Hemodynamic and Clinical Effects of Sildenafil in Patients With Pulmonary Arterial Hypertension Receiving Vasodilator Therapy. Mayo Clinic Proceedings 78:10, 1207-1213
     CrossRef

115. 115

     Hossein A Ghofrani, Frank Rose, Ralph T Schermuly, Horst Olschewski, Ralph Wiedemann, André Kreckel, Norbert Weissmann, Stefanie Ghofrani, Beate Enke, Werner Seeger, Friedrich Grimminger. (2003) Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. Journal of the American College of Cardiology 42:1, 158-164
     CrossRef

116. 116

     Robyn J Barst, Michael McGoon, Vallerie McLaughlin, Victor Tapson, Ronald Oudiz, Shelley Shapiro, Ivan M Robbins, Richard Channick, David Badesch, Barry K Rayburn, Robin Flinchbaugh, Jeff Sigman, Carl Arneson, Roger Jeffs. (2003) Beraprost therapy for pulmonary arterial hypertension. Journal of the American College of Cardiology 41:12, 2119-2125
     CrossRef

117. 117

     James R Runo, James E Loyd. (2003) Primary pulmonary hypertension. The Lancet 361:9368, 1533-1544
     CrossRef

118. 118

     Ventzislav Petkov, Wilhelm Mosgoeller, Rolf Ziesche, Markus Raderer, Leopold Stiebellehner, Karin Vonbank, Georg-Christian Funk, Gerhard Hamilton, Clemens Novotny, Bernhard Burian, Lutz-Henning Block. (2003) Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. Journal of Clinical Investigation 111:9, 1339-1346
     CrossRef

119. 119

     Rolf Ziesche. (2003) Konsensus-Empfehlungen der Arbeitsgruppe Pulmonalarterielle Hypertension der Österreichischen Gesellschaft für Lungenerkrankungen und Tuberkulose. Wiener Klinische Wochenschrift 115:10, 351-365
     CrossRef

120. 120

     Trenton D. Nauser, Steven W. Stites. (2003) Pulmonary Hypertension: New Perspectives. Congestive Heart Failure 9:3, 155-162
     CrossRef

121. 121

     Franco Recusani, Angela Di Matteo, Fabiana Gambarin, Andrea D'Armini, Catherine Klersy, Carlo Campana. (2003) Clinical and therapeutical follow-up of HIV-associated pulmonary hypertension. AIDS 17, S88-S95
     CrossRef

122. 122

     Monesha L. Gupta, M. Regina Lantin-Hermoso, P. Syamasundar Rao. (2003) What is new in pediatric cardiology. The Indian Journal of Pediatrics 70:1, 41-49
     CrossRef

123. 123

     Hossein A. Ghofrani, Frank Rose, Ralph T. Schermuly, Horst Olschewski, Ralph Wiedemann, Norbert Weissmann, Christian Schudt, Herrmann Tenor, Werner Seeger, Friedrich Grimminger. (2002) Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension. Critical Care Medicine 30:11, 2489-2492
     CrossRef

124. 124

     Evelyn M Horn, Robyn J Barst. (2002) Treprostinil therapy for pulmonary artery hypertension. Expert Opinion on Investigational Drugs 11:11, 1615-1622
     CrossRef

125. 125

     Myung H. Park, Robert L. Scott, Patricia A. Uber, Mandeep R. Mehra. (2002) Treatment of pulmonary hypertension: A promising new age. Catheterization and Cardiovascular Interventions 57:3, 395-403
     CrossRef

126. 126

     Kassiani Theodoraki, Panagiota Rellia, Apostolos Thanopoulos, Loukas Tsourelis, Dimitrios Zarkalis, Petros Sfyrakis, Theophani Antoniou. (2002) Inhaled iloprost controls pulmonary hypertension after cardiopulmonary bypass. Canadian Journal of Anesthesia/Journal canadien d'anesthésie 49:9, 963-967
     CrossRef

127. 127

     NS Paramothayan, TJ Lasserson, AU Wells, EH Walters. 2002. Prostacyclin for pulmonary hypertension in adults. .
     CrossRef

128. 128

     STUART LEHRMAN, PATRICIA ROMANO, WILLIAM FRISHMAN, AMBER RASHID, JAY DOBKIN, JOSEPH REICHEL. (2002) Primary Pulmonary Hypertension and Cor Pulmonale. Cardiology in Review 10:5, 265-278
     CrossRef

129. 129

     Hossein Ardeschir Ghofrani, Ralph Wiedemann, Frank Rose, Ralph T Schermuly, Horst Olschewski, Norbert Weissmann, Andreas Gunther, Dieter Walmrath, Werner Seeger, Friedrich Grimminger. (2002) Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. The Lancet 360:9337, 895-900
     CrossRef

130. 130

     Olschewski, Horst, Simonneau, Gerald, Galiè, Nazzareno, Higenbottam, Timothy, Naeije, Robert, Rubin, Lewis J., Nikkho, Sylvia, Speich, Rudolf, Hoeper, Marius M., Behr, Jürgen, Winkler, Jörg, Sitbon, Olivier, Popov, Wladimir, Ghofrani, H. Ardeschir, Manes, Alessandra, Kiely, David G., Ewert, Ralph, Meyer, Andreas, Corris, Paul A., Delcroix, Marion, Gomez-Sanchez, Miguel, Siedentop, Harald, Seeger, Werner, . (2002) Inhaled Iloprost for Severe Pulmonary Hypertension. New England Journal of Medicine 347:5, 322-329
     Full Text

131. 131

     M. Magliano, D. A. Isenberg, J. Hillson. (2002) Pulmonary hypertension in autoimmune rheumatic diseases: Where are we now?. Arthritis & Rheumatism 46:8, 1997-2009
     CrossRef

132. 132

     Jean-Michel Dogné, Xavier de Leval, Bernard Pirotte, Patricia Benoit. (2002) Latest discoveries in prostaglandin receptor modulators. Expert Opinion on Therapeutic Patents 12:8, 1225-1235
     CrossRef

133. 133

     Y. Matsukawa, O. Saito, M. Aoki, M. Abe, S. Nishinarita, S. Sawada, T. Horie, S. Naruse, M. Hiranuma. (2002) Long-term administration of beraprost, an oral prostacyclin analogue, improves pulmonary diffusion capacity in patients with systemic sclerosis. Prostaglandins, Leukotrienes and Essential Fatty Acids 67:1, 45-49
     CrossRef

134. 134

     Zhonghua Qi, Chuan-Ming Hao, Robert I. Langenbach, Richard M. Breyer, Reyadh Redha, Jason D. Morrow, Matthew D. Breyer. (2002) Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. Journal of Clinical Investigation 110:1, 61-69
     CrossRef

135. 135

     Tobias Gessler, Thomas Schmehl, Horst Olschewski, Friedrich Grimminger, Werner Seeger. (2002) Aerosolized Vasodilators in Pulmonary Hypertension. Journal of Aerosol Medicine 15:2, 117-122
     CrossRef

136. 136

     Stuart M. Lowson. (2002) Inhaled Alternatives to Nitric Oxide. Anesthesiology 96:6, 1504-1513
     CrossRef

137. 137

     Rubin, Lewis J., Badesch, David B., Barst, Robyn J., Galiè, Nazzareno, Black, Carol M., Keogh, Anne, Pulido, Tomas, Frost, Adaani, Roux, Sébastien, Leconte, Isabelle, Landzberg, Michael, Simonneau, Gérald, . (2002) Bosentan Therapy for Pulmonary Arterial Hypertension. New England Journal of Medicine 346:12, 896-903
     Full Text

138. 138

     Vallerie V McLaughlin. (2002) Medical management of primary pulmonary hypertension. Expert Opinion on Pharmacotherapy 3:2, 159-165
     CrossRef

139. 139

     P Le Houssine, M Karmochkine, F Ledru, D Batisse, C Piketty, M.D Kazatchkine, L Weiss. (2001) Hypertension artérielle pulmonaire primitive au cours de l’infection par le virus de l’immunodéficience humaine. Étude de neuf observations et revue de la littérature. La Revue de Médecine Interne 22:12, 1196-1203
     CrossRef

140. 140

     Christopher S Hayward, Anne M Keogh, Peter S Macdonald. (2001) Inhaled nitric oxide in cardiology. Expert Opinion on Investigational Drugs 10:11, 1947-1956
     CrossRef

141. 141

     Richard N Channick, Gérald Simonneau, Olivier Sitbon, Ivan M Robbins, Adaani Frost, Victor F Tapson, David B Badesch, Sébastien Roux, Maurizio Rainisio, Frédéric Bodin, Lewis J Rubin. (2001) Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study. The Lancet 358:9288, 1119-1123
     CrossRef

142. 142

     Robyn J. Barst. (2001) MEDICAL THERPAY OF PULMONARY HYPERTENSION. Clinics in Chest Medicine 22:3, 509-515
     CrossRef

143. 143

     Richard N. Channick, Lewis J. Rubin. (2001) NEW AND EXPERIMENTAL THERAPIES FOR PULMONARY HYPERTENSION. Clinics in Chest Medicine 22:3, 539-545
     CrossRef

144. 144

     Nazzareno Galié, Alessandra Manes, Angelo Branzi. (2001) MEDICAL THERAPY OF PULMONARY HYPERTENSION. Clinics in Chest Medicine 22:3, 529-537
     CrossRef

145. 145

     Ariane L Herrick. (2001) Development of agents for the treatment of systemic sclerosis. Expert Opinion on Investigational Drugs 10:7, 1255-1264
     CrossRef

146. 146

     Ronald G Tilton, Tommy A Brock, Richard AF Dixon. (2001) Therapeutic potential of endothelin receptor antagonists and nitric oxide donors in pulmonary hypertension. Expert Opinion on Investigational Drugs 10:7, 1291-1308
     CrossRef

147. 147

     B. Eberle, T. Kramm, S. Guth, E. Mayer. (2001) Efficacy of inhaled iloprost changes after pulmonary thrombendarterectomy in chronic thromboembolic pulmonary hypertension. European Journal of Anaesthesiology 18:Supplement 22, 38
     CrossRef

148. 148

     DUNBAR IVY. (2001) Diagnosis and Treatment of Severe Pediatric Pulmonary Hypertension. Cardiology in Review 9:4, 227-237
     CrossRef

149. 149

     Erika Berman Rosenzweig, Robyn J Barst. (2001) Novel therapeutics for the treatment of paediatric pulmonary arterial hypertension. Expert Opinion on Investigational Drugs 10:5, 811-823
     CrossRef

150. 150

     Richard M Breyer, Carey K Bagdassarian, Scott A Myers, Matthew D Breyer. (2001) P ROSTANOID R ECEPTORS : Subtypes and Signaling ¹. Annual Review of Pharmacology and Toxicology 41:1, 661-690
     CrossRef

151. 151

     Matthew D Breyer, Richard M Breyer. (2001) G P ROTEIN –C OUPLED P ROSTANOID R ECEPTORS AND THE K IDNEY. Annual Review of Physiology 63:1, 579-605
     CrossRef

152. 152

     Elizabeth S. Klings, Harrison W. Farber. (2001) Current Management of Primary Pulmonary Hypertension. Drugs 61:13, 1945-1956
     CrossRef

153. 153

     (2000) Aerosolized Iloprost for Primary Pulmonary Hypertension. New England Journal of Medicine 343:19, 1421-1422
     Full Text

Letters